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Flavivirus infections are the most prevalent arthropod-borne infections world wide, often causing severe disease especially among
children,theelderly,andtheimmunocompromised.Intheabsenceofeﬀectiveantiviraltreatment,preventionthroughvaccination
wouldgreatlyreducemorbidityandmortalityassociatedwithﬂavivirusinfections.Despitethesuccessoftheempiricallydeveloped
vaccines against yellow fever virus, Japanese encephalitis virus and tick-borne encephalitis virus, there is an increasing need for
a more rational design and development of safe and eﬀective vaccines. Several bioinformatic tools are available to support such
rational vaccine design. In doing so, several parameters have to be taken into account, such as safety for the target population,
overall immunogenicity of the candidate vaccine, and eﬃcacy and longevity of the immune responses triggered. Examples of
how bio-informatics is applied to assist in the rational design and improvements of vaccines, particularly ﬂavivirus vaccines, are
presented and discussed.
1.Introduction
Flavivirus infections are among the most important viral
pathogens of humans and animals, causing signiﬁcant
morbidity and mortality. They belong to genus Flavivirus
of the family Flaviviridae. Flaviviruses are transmitted via
arthropods and are classiﬁed into mosquito-borne and tick-
borne ﬂaviviruses. These groups of viruses are distinct not
only by their modes of transmission, but also phylogeneti-
cally and by the clinical manifestations of the infections they
cause [1]. Tick-borne ﬂaviviruses are mainly associated with
encephalitis and comprise a group of closely related viruses,
which collectively belong to the tick-borne encephalitis
(TBE) complex. The TBE complex comprises the Powassan
virus, Louping ill virus, Kyasanur Forest disease virus, Omsk
hemorrhagic fever virus, Langat virus and the Tick-Borne
encephalitis viruses (TBEV). The TBEV species includes
three subtypes which are all known to cause encephalitis in
humans: Western European (previously known as Central
European Encephalitis or CEE), Far Eastern (previously
known as Russian Spring and Summer Encephalitis or
RSSE), and Siberian (previously west-Siberian). Mosquito-
borne ﬂaviviruses are further divided based on phylogenetic
and antigenic diﬀerences. The Japanese encephalitis sero-
complex includes Japanese encephalitis virus (JEV), West
Nile virus (WNV) and Saint Louis encephalitis virus (SLEV).
The Dengue virus (DENV) group comprises an independent
serogroup of four closely related but antigenically distinct
serotypes. Finally, yellow fever virus (YFV), the prototype of
ﬂaviviruses, constitutes an independent serogroup [2].
The majority of ﬂavivirus infections are manifested by
mild acute febrile syndromes. A low percentage of infected
individuals may develop severe neurological, hepatic and/or
hemorrhagic disease with high mortality rates. JEV causes
frequentoutbreaksofmeningo-encephalitisinAsia,aﬀecting
mainly children [3]. WNV may also cause severe outbreaks
of meningo-encephalitis, with outbreaks conﬁned to West
Africa, Middle-East, and since 1999 also in North America.
WNV is now spreading all over the Americas, posing a risk
to millions of people [4]. DENV is endemic throughout
tropical and subtropical areas of the world where more
than 2.5 billion people are at risk of infection. Infection
with DENV may result in development of hemorrhagic
manifestations and/or shock in untreated patients [5]. YFV
causes serious infections manifested by fulminant hepatitis
and severe hemorrhagic disease. YFV still kills a considerable2 Journal of Biomedicine and Biotechnology
number of people annually, despite the availability of an
eﬀective vaccine [6].
Flaviviruses are relatively small (approx. 11kb) positive
single-stranded RNA viruses coding for three structural
(Capsid, C; Precursor membrane, prM; and envelope, E) and
seven nonstructural proteins (Figure 1(a)). The single open
reading frame (ORF) is ﬂanked by 5  and 3  untranslated
regions (UTR), the structures of which are important in
viral replication [7]. The E protein is the major component
of the virus bearing sites for attachment and fusion with
the host cells and induction of immune responses. Several
B- and T cell epitopes have been recognized on the E
protein [8, 9]. The E protein of ﬂaviviruses forms a head-
to-tail dimer both in solution and on the viral membrane
surface, with each monomer divided into three domains (D
I, II, and III, Figure 1(b)). DI folds into an eight-stranded
antiparallel β-barrel, containing about 120 residues and
divided in three segments. The two long loops between
these three segments form the dimerization DII, which
contains the fusion peptide. DIII contains the carboxy-
terminal 100 amino acids that form seven antiparallel β-
sheets. In contrast to DI and DII, this domain represents
an independently folding domain that can be expressed
as a recombinant protein. Studies on the B cell repertoire
upon ﬂavivirus infection suggest that the human antibody
response is predominantly directed to epitopes located in
DII [10, 11]. However, antibodies speciﬁc to epitopes in
DII have been shown to be weakly neutralizing, highly
cross-reactive with other ﬂaviviruses, and nonprotective in
animal models. On the other hand, the potent, type-speciﬁc,
neutralizing epitopes are located in the upper lateral surface
of DIII [12–14]. Mutations in the DIII region have been
associated with attenuated virulence or the ability of virus
to escape speciﬁc neutralization, suggesting a role of DIII
in receptor recognition [15]. Flavivirus infection triggers
both innate and adaptive immunity in na¨ ıve individuals.
In animal models, adaptive immune responses have been
shown to play an important role in controlling primary
WNV infection as exempliﬁed by the high viral loads and
high mortality observed in IgM deﬁcient mice. It has been
shown that the level of WNV-speciﬁc IgM at day four after
infection has a prognostic value [16]. The role of IgM in
controlling infection with other ﬂaviviruses is however still
unclear.AlthoughT-helper(CD4+)andT-cytotoxic(CD8+)
cellshavebeenshowntoplayaroleincontrollinginfectionof
mice with either WNV [17, 18] or DENV [19], the presence
of antibodies is generally considered more relevant in terms
of vaccine-induced protection.
For vector-borne viruses it is reasonable to assume that
eﬀective vector control would greatly reduce the morbidity
of infection with such viruses. In the case of ﬂaviviruses,
mosquito control has at least in the long run, proven to be
largely ineﬀective [20–22]. For example, eﬀorts to eradicate
the mosquito vectors of DENV during the 1970’s were
successfulandresultedinthedisappearanceofthevirusfrom
the region. However, as soon as these programs were discon-
tinued, Ae. aegypti (the main vector for urban transmission
of DENV) re-infested the region, which coincided with the
re-emergence of DENV. Therefore, vaccination against these
pathogens may be the most eﬃcient and eﬀective way to
controldisease.Infact,oneofthemosteﬀectivevaccinesever
developed is the live-attenuated vaccine against YFV [23].
This vaccine was developed in the late 1930’s by Theiler and
co-workers and although the correlates of protection even
today are not completely clear, it has been used to immunize
and protect more than 400 million people against yellow
fever.AlsolicensedvaccinesagainstJEVandTBEVinfections
in humans exist. Routine childhood immunization against
JEV has eliminated the disease from many Asian countries,
whereas the disease continues to cause devastating outbreaks
in countries where the vaccine is not used. The mouse brain-
derived inactivated vaccine is relatively expensive to produce
and the lack of long-term immunity and risk of allergic
reactions makes large-scale vaccination with this vaccine,
especially in Asia where it is most needed, not feasible. Cell
culture-derived inactivated and live-attenuated JEV vaccines
have been extensively used in China, but purity of these
vaccine preparations represents the main hurdle for approval
of these vaccines in Western countries. More recently a cell-
derived, alum-adjuvanted JEV vaccine was licensed for use
in adults in USA and some EU member states. However, the
longevity of the immune response to this vaccine is not yet
established. For other important ﬂavivirus such as WNV and
DENV, no vaccine is available yet.
This review aims to give a brief overview of ﬂavivirus
vaccine candidates and discuss how bio-informatics can
assist in the rational design and improvements of vaccines.
In doing so we will discuss examples of how bioinformatics
has been or could be used in the development of novel
generations ﬂavivirus vaccines. It is beyond the scope of
this review to summarize the recent advances in imm-
unoinformatics for the prediction of T and B cell epitopes
and the interaction of proteins with the immune system (the
reader is referred to the excellent review of Brusic et al. [24]
and the references therein).
2. RationalDesignof FlavivirusVaccines
We have entered a new era of vaccine development, where
rational design of candidate vaccines has replaced the
trial-and-error approach. Undoubtedly, the trial-and-error
approach has been successful in the past as exempliﬁed by
the success of the YFV vaccine, one of the most eﬀective
vaccines ever developed. Rational design of vaccines is a
step-wise approach as depicted in Figure 2:( 1 )i d e n t i f y
target antigen(s), (2) determine the vaccine platform, (3)
optimize factors for gene expression, (4) produce and
characterize vaccine, (5) test safety, immunogenicity and
eﬃcacy in animal models. The recent advances in molecular
biology and bio-information technology have contributed
signiﬁcantly to our understanding of viral structure, viral
replication, attenuation, and determinants of pathogenicity.
Understanding these aspects are crucial for identifying target
proteins. Several bio-informatic tools are available that can
help in the process of antigen identiﬁcation. The majority of
bioinformatic tools used in computational vaccinology how-
ever, focus on antigen presentation and processing, with the
ultimate goal to map T and B cell epitopes (step 5). AlthoughJournal of Biomedicine and Biotechnology 3
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Figure 1: (a) Flavivirus genomic RNA encoding one long ORF cleaved co- and post-translationally into three structural and seven
nonstructuralproteins.Theviralgenomeisﬂanked by5 and3 UTRswhichplayanimportantroleinvirustranscriptionandreplication.(b)
Three dimensional structure of the monomeric form of the E protein of DENV-2. Each monomer is divided into three discernable domains
(DI, II and III). Serocomplex and group speciﬁc cross reactive epitopes are mainly located on DI and II. DIII is the receptor binding domain
and contains mainly type speciﬁc epitopes. The potent neutralizing epitopes are located at the lateral site of DIII.
the mapping and identiﬁcation of highly immunogenic
epitopes on target antigens is important, several additional
steps need to be considered when embarking on rational
design of new generation vaccines against these viruses
(step 2 and 3). Common problems encountered during
development of vaccines include low yields of proteins and
consequently low immunogenicity.
3.InactivatedandSubunitCandidateVaccines
The great impact that ﬂavivirus infections have on public
health and the fact that prevention is diﬃcult to achieve
through vector control have made the development of
ﬂavivirus vaccines essential for long-term control and elim-
ination of these infections, and reduction of the associated
morbidity and mortality. The currently available vaccines
against YFV, JEV and TBEV have proven to be quite success-
ful. Eﬀorts are ongoing to develop safe and eﬀective vaccines
against the other medical important ﬂaviviruses. In addition
eﬀorts aiming to improve the existing ones are ongoing.
Almost all vaccine platforms have been used in the develop-
ment of candidate ﬂavivirus vaccines, ranging from whole
inactivated, live-attenuated, subunit, DNA and vectored
candidate vaccines (summarized in Table 1). The currently
licensed vaccines against JEV and TBEV contain formalin-
inactivated whole virus, puriﬁed from mouse brains [25]
(JEV) or cultured cells (JEV, TBEV). Studies to compare the
safety and immunogenicity of candidate vaccines based on
cell-derived inactivated JEV show promising results [26, 27].
This formalin-inactivated JEV vaccine is now licensed in
the USA and EU for use in adults. However, the duration
of immunity and the need for booster vaccination needs
to be further investigated [28]. There are several concerns
with the use of inactivated vaccines. They are expensive,
require two or three doses to achieve protective eﬃcacy,
and perhaps more importantly, require further booster
doses to maintain immunity [29]. Therefore, large scale
use of inactivated ﬂavivirus vaccines for humans may prove
problematic due to the need of an adjuvant to potentiate
the immune response and to provide long-lasting immunity.
Furthermore, formalin-inactivation may pose other safety
concerns as has been shown in case of respiratory syncytia
virus and human metapneumo virus [30, 31], although
extensiveuseofformalin-inactivatedJEVandTBEVvaccines
does not corroborate this concern.
Subunit ﬂavivirus vaccines, expressing recombinant E
protein, combination of prM-E or DIII alone, have been
shown to be eﬀective and immunogenic in animal models
[32, 33]. The minimalistic approach of using DIII alone
instead of full length E protein is based on the observations
that DIII contains epitopes responsible for type speciﬁc
neutralization, whereas DI and DII contain epitopes respon-
sible for cross-neutralization and/or sensitivity to disease
enhancement [10, 11]. Because DIII is poorly immunogenic,
the use of an adjuvant is necessary for eﬃcient induction of
immune responses.
A common problem of inactivated and subunit vac-
cines is the poor immunogenicity when compared to live-
attenuated vaccines. Given the safety issues often associated
with the use of live-attenuated vaccines, modern vaccinology
also focuses on the improvement of the immunogenicity of
inactivated and subunit vaccine candidates. Until recently
aluminium hydroxide (Alum) was the only adjuvant reg-
istered for human use. Alum triggers antibody responses
and T-helper 2 responses, but no CD8+ T cell immune
responses. Increasing understanding of the mechanisms that
leads to protective versus detrimental immune responses
will be instructive in the rational choice and design of
novel adjuvants. For example, the activation of several Toll
like receptors (TLR) has been shown to stimulate innate
and orchestrate adaptive immune responses via stimulation
of antigen presenting cells. Several studies have shown
the potential of TLRs agonists as eﬀective adjuvants [34–
36]. CpG oligodeoxynucleotides were shown to be potent4 Journal of Biomedicine and Biotechnology
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Figure 2: Steps involved in the rational design of vaccines. A number of parameters should be taken into account from choosing the right
immunogen until the selection of candidate vaccines for clinical trials. Several bioinformatics tools can be applied in this process to assist in
the improvement of antigen selection, maximizing expression, determination of immunogenicity and selection of candidate vaccines.Journal of Biomedicine and Biotechnology 5
Table 1: Summary of ﬂavivirus candidate vaccines based on diﬀerent vaccine platforms.
Type of vaccine Virus Antigen Comments
Inactivated/killed
JEV Whole virus Licenced for human use
DENV-2 Whole virus Pre clinical studies in mice and non-human primates
WNV E, prM, whole virus Low immunogenicity, use of adjuvant necessary
Subunit
DENV-2 D III, NS1, E protein Immunogenicity tested only in mice
DENV-4 C-M-E-NS1 Immunogenicity tested only in mice
WNV D III, E protein, NS1 Low immunogenicity, only tested in mice
JEV prM-E Immunogenicity tested only in mice
DNA
DENV prM-E, NS1 Low immunogenicity
JEV E Low immunogenicity
WNV E, prM, C Low immunogenicity
Live attenuated
YFV Licenced for human use
Mono- and tetravalent DENV Phase I, and II clinical trials ongoing
JEV Phase I and II clinical trials conducted
WNV
Vectored WNV E, prM Vectors used: MVA, MV, AdV, pox-, alphaviruses
stimulators of TLR-9 and able to signiﬁcantly enhance
both the humoral and cellular immune responses to sev-
e r a lv i r u s e si nm i c e[ 37, 38]. Furthermore, the use of
CpG resulted in substantial reduction of the antigen dose
neededinseveralmodels.Severalprograms(e.g.,DyNAVacS,
Table 2) allow optimization of CpG content in the gene of
interest, which may enhance vaccine immunogenicity. An
interesting development in this ﬁeld is the availability of a
database (TollML) to retrieve and deposit agonists for the
diﬀerent TLR (Table 2). In this database, the known struc-
tural motifs of TLRs are deposited allowing for structural
modelling of other TLRs. Furthermore the ligands of TLRs
can be easily retrieved. Elucidation of the crystal structure
of TLRs and improvement of powerful bioinformatics tools
for protein homology and ab intitio modelling will allow
structure-based design of safe and eﬀective TLR agonists that
could be subsequently used as adjuvants for vaccines [39–
41]. The potential of such adjuvants was recently demon-
stratedinastudythatreportedhowthepoorlyimmunogenic
DIII of WNV was remarkably more immunogenic in mice
when fused with the TLR-5 agonist ﬂagellin [42].
4. Live-AttenuatedVaccine Candidates
In light of the safety issues that may be related with
the use of current experimental adjuvants, the concept
of using live-attenuated or vectored vaccines is more and
more preferred over that of inactivated or subunit vaccines.
The current vaccine against YFV is a live-attenuated whole
virus vaccine, which has been shown to be safe and highly
eﬀective. The advantage of live-attenuated vaccines is that
both antibody and T cell responses are induced, although,
there may be risks related to the use of live-attenuated
vaccines [43]. For instance, the eﬀorts for the development
of a successful vaccine against DENV have mainly focused
on the attenuation of the four DENV serotypes through
several passages in cell culture and use of these viruses
in monovalent or multivalent formulations. The leading
hypothesis to explain pathogenesis of DENV infections is
the antibody-dependent enhancement of infection (ADE),
which suggests that cross reactive subneutralizing antibodies
may enhance the infection of target cells, rather than protect
them against infection [5]. Since the borderline between
protective immunity and disease enhancing immunity is not
well deﬁned, the most eﬀective vaccine against DENV would
be one that confer solid immunity against all four serotypes.
A live-attenuated tetravalent DENV vaccine candidate has
been shown to be immunogenic in ﬂavivirus na¨ ıve and
immune nonhuman primates [44, 45], whereas phase I and
II clinical trials in humans have shown promising results
[46–48]. The molecular basis for attenuation of wild type
virus through passage on cell cultures or in animals is
usually not understood. A more rational way of generating
live-attenuated vaccines is by understanding correlates of
virulence. Several algorithms have been designed and are
available either free online or as commercial software
programs to aid in the prediction of secondary structures
of RNA (Table 2). The secondary structures of the 5  and
3 -UTRs of several ﬂaviviruses, including YFV, DENV, and
TBEVhavebeenpredictedandconservedstructuralelements
that are important in viral replication were identiﬁed [49–
52]. In a series of studies with DENV-4, the secondary
structure of wild type viruses were predicted and subsequent
studies were designed to create deletion mutants lacking
structural elements that could inﬂuence viral replication. It
was indeed shown that when a 30-nucleotide region was
deleted, the mutant virus was attenuated and had lost its
ability to be transmitted by Ae. aegypti. Subsequently it was
shown that these mutant viruses were able to induce strong
immune responses in rhesus macaques and in humans,
similar to what is seen with wild type viruses [53, 54]. The
success of the DENV-4 Δ30 was followed by similar results
using a DENV-1 Δ30 mutant virus in vaccination trials of
humans and nonhuman primates [55]. In the same line of6 Journal of Biomedicine and Biotechnology
Table 2: Selection of servers and programs that could assist in the rational design of vaccines.
Server Web address Server description Availability
ORF-FINDER http://www.ncbi.nlm.nih.gov/projects/gorf/
Program identiﬁes open
reading frames in a
genome.
Free online
GeneMark http://exon.biology.gatech.edu/
A set of gene prediction
servers for prokaryotes,
eukaryotes and viruses
Free online
NERVE http://www.bio.unipd.it/molbinfo/
In silico prediction of
vaccine candidates from
complete proteomes of
bacterial pathogens
Free for
download
Gene Composer http://www.genecomposer.net/
Gene Composer is a
software program for
rational design or
optimization of genes
Free demo for
1 year
PromoterScan http://www-bimas.cit.nih.gov/molbio/proscan/
Predicts Promoter regions
based on scoring
homologies with putative
eukaryotic Pol II promoter
sequences
Free online
ATGpr http://ﬂj.hinv.jp/ATGpr/atgpr/index.html
A program for identifying
the initiation codons in
cDNA sequences
Free online
PolyApred http://www.imtech.res.in/raghava/polyapred/
P o l y A p r e di saS V Mb a s e d
method for the prediction
of polyadenylation signal in
human DNA sequence.
Free online
NetGene2 http://genome.cbs.dtu.dk/services/NetGene2/ Predictions of splice sites in
human Free online
SignalP http://www.cbs.dtu.dk/services/SignalP/
Signal peptide and cleavage
sites in prokaryotic and
eukaryotic sequences
Free online
Optimizer http://genomes.urv.es/OPTIMIZER/
Aw e bs e r v e rf o r
optimization of codon
usage of a DNA sequence to
increase its expression level.
Free online
CodonExplorer http://bmf2.colorado.edu/codonexplorer/index.psp
Online tool for analyzing
GC content and codon
usage frequency
Free online,
registration
required
STAR http://biology.leidenuniv.nl/∼batenburg/STROrder.html
STAR simulates the folding
pathway of RNA and is able
to predict formation of
pseudoknots formation
Commercially
available
VIENNA package http://rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi
RNAfold predicts
secondary structure of
single stranded RNA or
DNA based on minimum
free energy predictions
Commercially
available
mFOLD http://mfold.bioinfo.rpi.edu/
Prediction of RNA and
DNA secondary structure
based on thermodynamic
methods
Free online
DyNAVacS http://miracle.igib.res.in/dynavac/
An integrative tool for
optimized DNA vaccine
design
Free onliune
AlgPred http://www.imtech.res.in/raghava/algpred/
Algpred allows prediction
of allergens based on
similarity of known epitope
with any region of protein
Free onlineJournal of Biomedicine and Biotechnology 7
Table 2: Continued.
Server Web address Server description Availability
BIMAS http://www-bimas.cit.nih.gov/molbio/hla bind/ Server for prediction of
MHC-I epitopes Free online
EpiPredict http://www.imtech.res.in/raghava/mhc2pred/
Software to predict
HLA-class II restricted T
cell epitopes and ligands
Free online
SYFPEITHI http://www.syfpeithi.de/
Server for prediction of
MHC-I and MHC-II
epitopes
Free online
RANKPEP http://bio.dfci.harvard.edu/RANKPEP/
Server for prediction of
MHC-I and MHC-II
epitopes
Free online
CEP http://202.41.70.74:8080/cgi-bin/cep.pl
Server for prediction
conformational B cell
epitopes
Free online
Bcipep http://www.imtech.res.in/raghava/bcipep/pep src.html
Bcipep is a database with a
collection of immunogenic
Bc e l lp e p t i d e s
Free online
ABCpred http://www.imtech.res.in/raghava/abcpred/
Server for prediction
conformational B cell
epitopes
Free online
ePitope http://www.epitope-informatics.com/ Server for prediction linear
B cell epitopes
Online,
commercial
TollML http://tollml.lrz.de/
A user-friendly database to
retrieve sequence and
structural data as well as
ligands for TLRs.
Free online
Virology Bioinformatics http://www.bioinfo.de/isb/2008/08/0008/
A collection of
bioinformatic tools for
virology research
Free online
VBRC http://athena.bioc.uvic.ca/
VBRC provides access to
viral genomes and a variety
of bioinformatic tools for
comparative genomic
analyses
Free online
research, DENV-2 and DENV-3 Δ30 mutants were found to
be under-attenuated [56, 57]. Using prediction algorithms
for secondary structure of RNA a larger region in the
3 UTR of DENV-3 was deﬁned as possibly associated with
attenuation and the new mutant virus that was engineered
based on these predictions showed a much more promising
phenotype in preclinical studies [58]. Similarly, prediction of
RNA secondary structure of YFV strains revealed diﬀerences
between attenuated vaccine strains and wild type viruses.
In particular, the conserved long stable hairpin (LSH, a
crucial structural element for virus replication) was shorter
in vaccine strains than in wild type viruses [50]. As depicted
in Figure 3, a 30-nt deletion in the 3 UTR of DENV-3 results
in altered secondary structure of the RNA and possibly
loss of structural elements necessary for replication. These
examples demonstrate that in silico simulation of RNA
secondary structure of viral genomes could be a ﬁrst step
in rational design of candidate vaccines. Similarly, it has
been shown that the nucleotide sequence of the attenuated
YFV vaccine strain diﬀers only 68 nucleotides (translated
in 32 amino acid diﬀerences) from the parental wild type
virulent strain, suggesting that some of these mutations
might be associated with virulence and attenuation [59]. The
advances in reverse genetics technology allow construction
of recombinant viruses with the desired mutations. Such
mutant viruses are attractive attenuated vaccine candidates,
which could also be used as vectors to express genes of
interest, or serve as backbones for chimeric vaccines.
5. DNA andVectoredVaccine Candidates
A common problem encountered during the development of
DNA and some vectored vaccines is the low immunogenicity
of such vaccine candidates. Variation in transgene stability
and level of protein expression are typically attributed to
properties of the promoter elements and recombinant gene.
5.1. Transcriptional Regulator
5.1.1. Promoter. Molecular biology has made a signiﬁcant
contribution to the development of new generation vaccines.
Among the ﬁrst steps in development of novel generation
vaccines is the cloning and expression of genes that encode8 Journal of Biomedicine and Biotechnology
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Figure 3: Prediction of RNA secondary structure of the 3 UTR
of DENV-3 strain H87 (DENV-2 Jamaica strain) using the GA
algorithm included in the STAR software package. In the top panel
is depicted the predicted structure of the naturally occurring strain
(shown with arrows the predicted pseudoknot and the conserved
LSH structures), bottom panel: predicted structure after in silico
introduction of a 29-nt deletion in the proximal part of the UTR.
The LSH is preserved but the pseudoknot is lost after deletion. LSH:
long stable hairpin, ps: pseudoknot.
highly immunogenic proteins of the virus. Several plasmids
have been designed for cloning and expression of both
prokaryotic and eukaryotic genes (Figure 4(a)). Obviously,
the choice of plasmid for cloning of the genes of interest
depends on the type of vaccine platform which is envisaged:
subunit, DNA, or vectored. For example, in case of subunit
vaccines, it is imperative for the antigen used in the vaccine
to resemble its native form as much as possible. Therefore, it
is important to realize that posttranslational modiﬁcations,
which diﬀe rb e t w e e np r o k a r y o t e sa n de u k a r y o t e sm a ya ﬀect
the formation of B cell epitopes. For DNA and vectored
vaccines it is well appreciated that antigen expression levels,
determined at both the transcriptional and translational
level, aﬀect immunogenicity and eﬃcacy of vaccines. Pro-
moter and enhancer elements aﬀect the levels of messenger
RNA (mRNA) available, which have a signiﬁcant impact on
the protein expression levels. The human cytomegalovirus
(CMV) immediate-early and the simian virus 40 (SV40)
early promoters are the most commonly used transcriptional
regulators. Several studies have shown that virus-derived
promoters, including the CMV, SV40, and Rous sarcoma
virus (RSV), are stronger than other eukaryotic promoters
[60] in driving gene expression. In particular the CMV
promoter has been shown to be a potent regulator of
transcription compared to most other viral promoters [60].
The sensitivity of the CMV promoter to inactivation by
cytokines and methylation, especially in muscle tissues [61–
63], in addition to the regulatory problems that may be
associated with the use of transcriptional elements derived
from pathogenic viruses, have prompted the search and
use of other potent promoters. Promoter regions can be
predictedinsilicoinagivensequenceand/orvector(Table 2).
To this end, mammalian promoters including β-actin [64],
human Muscle Creatine-Kinase (MCK) [65], human elon-
gation factor 1α (EF-1α)[ 66], human phosphoglycerate
kinase-1 (PGK) [67], major histocompatibility class II [68],
human telomerase reverse transcriptase (TRT) [69–71], and
tissue plasminogen activator (tPA) [72]p r o m o t e r sh a v eb e e n
tested. It is important to realize that promoters may regulate
expression of genes in all cell types (ubiquitous) or they may
express tissue-speciﬁc activity. Therefore, careful considera-
tion must be given to the selection of the promoter driving
transgene expression. For instance, while CMV promoter
drives transient, but high-level expression of proteins, RSV
promotes high-levels of gene expression for a longer time.
Therefore, the eukaryotic promoter EF-1α,w h i c hp r o v i d e s
long-term and high-level gene expression [73]m a yr e p r e s e n t
an alternative to viral promoters like RSV. Their activity may
be increased by the addition of introns upstream the gene
sequence as exempliﬁed by CMV driven vectors [74–77].
This increase in protein expression has been attributed to
the presence of enhancer elements in the intron sequence
and increased rate of polyadenylation and RNA splicing
[77]. However, inclusion of an intron sequence must be
applied with caution as it may also lead to aberrant splicing
[78]. The use of programs that predict splicing (Table 2)
in the context of promoter and intron could help in the
rational design or choice of transcriptional units that do
not result in aberrant gene splicing. The use of synthetic
promoter/enhancersequencesfromdiﬀerentsourceshasalso
proven to be promising. For example the CAG promoter, a
chimera of a CMV enhancer, a chicken β-actin promoter and
ar a b b i tβ-globulin splicing site was shown to induce strong
expression of genes in several tissues [79–81]. Although
diﬀerent promoters have been used in the design of ﬂavivirus
candidate DNA vaccines, the eﬀect of diﬀerent promoters
on immunogenicity and eﬃcacy has not been investigated
[82]. However, the choice of promoters has been shown
to aﬀect immunogenicity of DNA vaccines against human
immunodeﬁciencyvirustype1,humanhepatitisBvirus,and
herpes simplex virus type 1 [83–85], and therefore should be
taken into account when designing candidate vaccines.
5.1.2. Polyadenylation. Polyadenylation (addition of a polyA
tail) of eukaryotic mRNA has several functions: (i) it aids
the export of the mRNA from the nucleus, (ii) it protects
the molecule from enzymatic degradation in the cytoplasm,
(iii) it directs termination of transcription, and (iv) enhances
translation, although poly(A) is not necessary for translation
of all mRNAs. In principle, polyadenylation occurs in threeJournal of Biomedicine and Biotechnology 9
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Figure 4: (a) A basic expression plasmid showing the CMV promoter, multiple cloning sites (MCS) and a BGH polyadenylation site, (b)
Predicted signal peptide sequence for the WNV E protein. The signal peptide probability is determined by the positive polarity of the n-
region, the hydrophobicity of the h-region and the uncharged amino acids occupying positions −1a n d−3 in the c-region. The cleavage site
is located in the c-region and is determined by the physicochemical characteristics and length of the n- and h-regions.
stages: polyadenylation site choice, cleavage of the pre-
mRNA, and addition of the poly(A) tail to the newly formed
3 -end [86]. The ﬁrst step, polyadenylation site choice, can
be deﬁned as the preparation of the pre-mRNA to allow
eﬃcientandaccuratecleavage[87].Anymutationofthepre-
mRNA sequence elements involved in polyadenylation site
choice may result in the ineﬃcient polyadenylation of the
pre-mRNA, limited nuclear export and decreased translation
of the protein [86, 88, 89]. Therefore, polyadenylation site
choice is an important ﬁrst step in polyadenylation and
is essential for optimal gene expression. The poly(A) site
of SV40 is highly eﬃcient and frequently used as a late
polyadenylation signal in many DNA plasmids. It contains
eﬃciency elements both upstream and downstream of the
AAUAAA region, and the downstream region contains three
deﬁned elements, two U-rich elements and one G-rich
element, instead of the single U- or GU-rich element found
in most polyadenylation signals [90]. The bovine growth
hormone polyadenylation signal (BGH) is another highly
eﬃcientandfrequentlyusedpoly(A)signalinDNAvaccines.
It is known that the BGH poly(A) pre-mRNA forms an
extensive hairpin loop secondary structure at the 3 -UTR
[91], possibly explaining the more eﬃcient polyadenylation
sequence. However, although both SV40 and BGH poly(A)
signals have been shown to be highly eﬃcient, depending on
the background of the constructs used, they may negatively
inﬂuence plasmid stability. The issue of promoter and
poly(A) signal becomes particularly important when design-
ing DNA vaccines. Ineﬃcient nuclear delivery of plasmid
DNA remains a major bottleneck in DNA vaccination [92],10 Journal of Biomedicine and Biotechnology
which may be increased by addition of a nuclear localization
signal [93]. However, nuclease degradation of plasmid DNA
afteradministrationandduringtraﬃckingtothecellnucleus
represents one of the main reasons of this ineﬃciency
[94]. In this respect it has been shown that there is a
correlation between the number of purine-rich regions in
the poly(A) site and the susceptibility of the plasmid to
nuclease degradation [95, 96]. This indicates the importance
of this region in conferring plasmid stability in addition to
determining eﬃciency of post-transcriptional modiﬁcation
[95]. BGH has been shown to have the highest frequency
of purine-rich regions compared to the SV40 poly(A)
sequence and hence renders plasmids more susceptibility
to degradation. Consistently, modiﬁcation of the poly(A)
site was shown to increase plasmid stability, although it
negatively aﬀected protein expression levels [95]. Taken
together, plasmid resistance should be taken into account
during DNA vaccine design and more eﬀorts should be
deployed to understand how rational modiﬁcation of the
poly(A) signal sequence may increase plasmid stability while
maintaining the same levels of protein expression.
5.2. Translational Regulator
5.2.1. Codon Usage. It is generally appreciated that not all
codons within a synonymous codon family are used at
the same frequency, a phenomenon called “codon usage
bias”.Optimalcodonsaredeterminedbyhighconcentrations
of particular transfer RNAs (tRNAs) and strong codon-
anticodon interactions [97, 98]. In general, closely related
organisms use similar codons compared to taxonomically
distant organisms [99–101]. In addition to the codon
usage bias between diﬀerent organisms, there are substantial
diﬀerences between genes of the same organism [102, 103].
Certain codons are preferentially used in highly expressed
genes [98], while use of rare codons may represent a sup-
pressive mechanism of gene expression under inappropriate
conditions. Codon usage inﬂuences translation initiation
[104, 105], protein folding [106], and consequently protein
expression levels. Therefore, codon usage adaptation of the
target gene to those of the expression host is one way
to enhance translational eﬃciency. Methods for optimising
genes for high expression in prokaryotes, yeast, plants, and
mammalian cells are becoming increasingly sophisticated
and well-established in the ﬁeld of vaccinology (Table 2).
One measure of codon quality is the Codon Adaptation
Index (CAI), a measure for the relative adaptiveness of
the codon usage of a gene towards the codon usage of
highly expressed genes. The index uses a reference set of
highly expressed genes from a species to assess the relative
merits of each codon, and a score for a gene is calculated
from the frequency of use of all codons in that gene
[107]. Optimizing codon usage has been shown to increase
immunogenicity of candidate vaccines against both viruses
andbacteria[108–114].Theincreasedimmunogenicityisthe
resultofimprovedprotein transcription andtranslation rate,
which leads to stimulation of stronger antibody and T cell
responses.Inaddition,theoptimizedGCcontentcontributes
to a better induction of T cell responses through the TLR-9
pathway. Several programs are now available to analyse and
adaptcodonusageofatransgenetothatofthehost(Table 2).
5.2.2. Kozak and Leader Sequences. Sequences surrounding
the start codon (AUG) within the mRNA, the so-called
kozak sequences, inﬂuence the quality and quantity of the
synthesized protein. The optimal context for initiation of
translation in mammals is GCCRCCAUGG [115]. Optimal
kozak sequences contain a high frequency of A at the −3
position and G at positions −9, −6 ,a n d+ 4 ,a n dAo rCa r e
predominantly found at positions −5, −4, −2, and −1[ 82,
116].Althoughitisrecommendedtoprovideviralgeneswith
a kozak sequence, most DNA and vectored vaccines have not
included this sequence in their cloning strategy. Prokaryotic
genes possess an analogue of the kozak sequences, the Shine-
Dalgarno (SD). Analysis of several E-coli genes indicates
that SD sequences are present in virtually all genes [115].
Therefore, expression of genes in prokaryotic and eukaryotic
systems may beneﬁt from the insertion of respectively an SD
and kozak sequence around the translation initiation codon.
Leader sequences encode signal peptides that play an
importantroleintargetingsecretoryandmembraneproteins
in both prokaryotes and eukaryotes to the right compart-
ment. Leader sequences are usually found at the N-terminal
side of proteins, although they may also be located within
a protein or at its C-terminal end [117]. Signal peptides
are divided into three diﬀerent regions: N-terminal (n),
hydrophobic (h), and cleavage (c) (Figure 4(b)). The h-
region, which is the most essential part responsible for
targeting and membrane insertion, comprises 6–15 amino
acid residues. The c-region consists of small uncharged
residues at positions −3a n d−1, which determines the site
and probability of signal cleavage. Cleavage is more likely to
occur when an amino acid with a short side-chain is present
at the −1 position and no charged amino acids are present at
the −3 position (reviewed in [118]). In addition, the amino
acid composition of the n-region as well as the length of the
h-region may aﬀect cleavage probability [118]. The choice of
the leader sequence may also inﬂuence the behaviour of pro-
teins as type I or type II as well as the rate of protein folding
within the cell. In this regard, it is interesting to note that
the codon usage of signal peptides plays an important role
in correct folding of proteins [119, 120]. The use of signal
sequences have been shown to aﬀect vaccine immunogenic-
ityandisthereforeanimportantparameterinrationaldesign
ofvaccines[121–124].Inthisrespect,signalpeptidecanhave
an “early” or “delayed” eﬀect on protein maturation and
secretion in that it can either cleave the signal peptide soon
after translocation in the ER or delay its cleavage. It is thus
of paramount importance to use custom designed vectors
that carry the gene of interest for candidate DNA or subunit
vaccines and with the use of bioinformatic tools determine
the presence and potency of kozak and leader sequences.
6.FlavivirusDNA andVectoredVaccines
Plasmids have been studied as potential candidate vaccines
against several pathogens. Immunogenicity of inactivated,
subunit, or vectored vaccines may be compromised in areasJournal of Biomedicine and Biotechnology 11
where several ﬂaviviruses cocirculate due to interference of
pre-existing crossreactive antibodies with the vaccine. DNA
vaccines may therefore represent an attractive alternative for
use in ﬂavivirus endemic areas, since these are not sensitive
to neutralization by ﬂavivirus cross-reacting antibodies.
However, most DNA vaccine candidates have not proven
suﬃciently immunogenic, although many have provided
protection against disease and death in animal models [125,
126].Duringvirusreplication,prMisessentialforprotection
of the E protein against denaturation due to low pH and
some believe it is crucial for correct folding of the E protein.
Consequently, most candidate DNA vaccines encode the
complete prM and E genes of ﬂaviviruses. It is diﬃcult to
explain why certain vaccines proved superior to others, since
diﬀerent vaccines were constructed using diﬀerent plasmids.
Comparison of diﬀerent JEV DNA vaccines revealed diﬀer-
ences in kozak sequences surrounding the start codon [82],
and diﬀerences between signal peptides of the prM. These
diﬀerences have been proposed to aﬀect the immunogenicity
of the diﬀerent candidate vaccines [82]. The major diﬀerence
between the diﬀerent signal peptide sequences are the length
andcompositionofthen-region.Signalpeptideswithashort
n-region and with no positively charged amino acids may
p r o m o t eat y p eIo r i e n t a t i o n ,w h i c hm a ya ﬀect processing
eﬃciency and topology of the expressed prM and E proteins,
and consequently immunogenicity [127, 128]. The predic-
tion of optimal signal peptides and use of codon optimiza-
tion programs have been exploited in the development of
WNV candidate vaccines, which proved to be eﬀective in
animal models and in humans [72, 129, 130]. This is the
ﬁrst ﬂavivirus DNA vaccine to reach phase I clinical trials,
showing promising safety and immunogenicity results [130].
Theabilityofsuchvaccinestoinduceneutralizing antibodies
can be explained by the formation of virus-like particles
with morphology similar to virus particles. The choice of
complete versus truncated E proteins may also determine
whether proteins are secreted or will remain membrane-
anchored and thus determine vaccine immunogenicity [131,
132]. Although DNA vaccines have not been shown to be
very immunogenic, proof-of-principle for DNA vaccines has
beenvalidatedwithanumberofﬂavivirusvaccinecandidates
in a variety of animal models. The concept of DNA vaccines
asagenericﬂavivirusvaccineplatform,especiallyinendemic
areas, still remains viable and attractive. Many strategies
are being explored to enhance the immunogenicity of DNA
vaccines. The easiest and most straightforward approach
that can be quickly transitioned to a clinical trial setting
is vaccine delivery by a needle-free jet injector [133]. This
approach has shown much potential and is the ﬁrst and most
forward way to enhance immunogenicity of DNA vaccines.
Other approaches include the co-expression of cytokines
[134, 135] or inclusion of sequences that enhance MHC class
I and II antigen presentation [136–138]. Another promising
DNA vaccine was recently described based on a single-round
infectious particle system [139], which resulted in enhanced
immunogenicity and eﬃcacy against WNV.
Several viral vectors have been developed and eval-
uated as candidate vaccines against ﬂaviviruses, includ-
ing poxviruses [140–143], adenoviruses [144–146], measles
virus [147], alphavirus [148–150], and vesicular stomatitis
virus [151]. Modiﬁed Vaccina virus Ankara (MVA) is an
orthopoxvirusvaccinevectorofparticularinterest.MVAhas
been shown to be immunogenic and safe, even in severely
immunocompromised animals [152]. The safety proﬁle of
MVA can be explained by the fact that the virus establishes
only one round of replication, a property that is stably
maintained over several passages. Furthermore, MVA and
other viral vectors like the complex adenovirus (CAdVax),
can harbour multiple genes, rendering them more suitable
candidates for developing pan-ﬂavivirus vaccines [153]. A
variety of MVA promoters such as PmH5, P7.5, P11K,
Psyn, PsynII, and Pk1L have been used for regulation of
gene expression. Optimization of target DNA sequences
and use of strong but not overexpressing promoter systems
have been applied in the development of several MVA
vaccine candidates. Viral vectors expressing prM and E,
E alone or DIII have all been shown to be eﬀective in
animal models [141, 144–146, 151, 154, 155]. Most vectored
vaccines developed against ﬂaviviruses were not optimized
for polyadenylation, codon and promoter usage, providing a
partial explanation for the often moderate immunogenicity
observed in many cases. Similar to the immunogenicity of
DNA vaccines, that of vectored vaccines can be improved by
the careful choice and reconﬁguration of promoters [62, 66,
156], optimizing gene codon usage, inclusion of a consensus
Kozak sequence and this all by exploiting the power of
bioinformatics (Table 2).
Another promising approach for vectored vaccines is the
chimeric vaccines developed using the YFV-17D backbone.
Chimeric WNV candidate vaccines based on a related
ﬂavivirus vector, the YFV vaccine strain 17D, are among the
most promising vectored WNV vaccine candidates to date
[157]. A vaccine based on this technology is now licensed
for use in horses [158] and a similar one has undergone
phase I and phase II clinical trials in humans. These chimeric
vaccines exploit the safety record of the yellow fever virus
vaccine strain 17D in healthy individuals, and the immuno-
genicity of this vector that has already been shown in exper-
imental animals and horses as well as for a vectored vaccine
againstotherﬂaviviruses,suchasJEVandDENV[159–161].
7. Concluding Remarks
Despitenumerousandcontinuouseﬀortstodevelopsafeand
eﬀectivevaccinesagainstﬂavivirusescausingdiseaseofmajor
medical importance, there are still areas of vaccine research
that need to be explored in this respect. The traditional trial-
and-error approach that has dominated the ﬁeld of ﬂavivirus
vaccine development until today may beneﬁt from recent
advances in biotechnology and bioinformatics allowing for
a more rational approach in vaccine design. The steps that
should be taken to optimally exploit bioinformatics in the
rational design of vaccines are shown in Figure 2.
Minimalistic approaches using certain genes or even
parts thereof associated with high immunogenicity might
replace whole virus-based candidate vaccines. There are
several advantages in using subunit over whole virus12 Journal of Biomedicine and Biotechnology
vaccines. A notorious example from the ﬂavivirus ﬁeld is
the immune enhancement theory that is frequently stated to
explain the pathogenesis of severe DENV infections (ADE,
see above). In light of this hypothesis, an ideal DENV
vaccine should elicit strong antibody responses to type
speciﬁc and not to cross-reactive epitopes. In this regard, the
DNA and vectored vaccines tested till now did not induce
better immune responses than tetravalent live-attenuated
vaccines. Taking advantage of, for instance, the optimization
of gene and protein expression and development of safe and
potent adjuvants, seems to be imperative in the rational
design of DENV vaccines. Finally, bioinformatics should
play a prominent role in the process of gene optimiza-
tion as well as the downstream processes of testing and
selection.
Considering the advantages and disadvantages of inacti-
vated, live-attenuated, subunit, and DNA vaccines, vectored
vaccines should be considered among the most promising
ones. The advantage of vectored vaccines over the others
is that long-lived B and T cell responses may be induced.
Furthermore, vectored vaccines based on YFV, MVA, or
Adenovirus have a well-established safety record. Still, the
immunogenicity and eﬃcacy of vectored vaccines should
be improved by using the knowledge and tools acquired
from the DNA vaccine ﬁeld. To this end, bioinformatic
tools routinely used for design of DNA vaccines should also
be used for careful design of synthetic genes for optimal
protein expression taking the genetic background of the
vector and host into account. However, bioinformatics is
not systematically used to guide the rational development
of safer vaccines. Several tools are available that can be used
separately to eliminate for instance allergenic, immunosup-
pressive, oncogenic, or DNA binding sequences from the
target protein. However, there is a need for integration of
these tools into a software program that will allow a more
rational design of safe and eﬀective vaccines.
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